Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Discontinuation rates due to adverse events remain low across studies (approximately 4-10%), indicating good overall tolerability
Potential benefits: Improved mobility in aging dogs Support for wound healing Aid in post-surgical recovery 3
Zhang Y, Li G, Ji C
Both peptides show published activity across rodent and cell-culture tissue-repair models without binding a single canonical receptor, distinguishing the blend from receptor-targeted compounds
Phase 2 cagrilintide alone ~10.8% body weight reduction at 26 weeks (4.5mg) Phase 2 CagriSema combo ~15.6% body weight reduction at 32 weeks Phase 3 REDEFINE 1 ~22.7% body weight reduction at 68 weeks Phase 2 CagriSema combination trial The Phase 2 trial of CagriSema was published in The Lancet in 2023, and its results attracted immediate attention
US$ 24.44
US$ 24.04
US$ 29.06
US$ 27.96
US$ 20.21
US$ 28.86